Neuroinflammation & membrane integrity

What actually decides this outcome, in order of size

Glial inflammation is a plausible mechanism and a poor purchase, because what decides whether it lifts is almost never the molecule you add. Ranked by how much of the outcome each one owns:

1. Whether the thing driving it is still running. Microglia do not stay primed for no reason, and a primed state is read out as IL-1 beta and TNF release rather than as a feeling. Intermittent nocturnal hypoxia, a glycemic load that spends six hours a day above 140 mg/dL, alcohol, and an untreated thyroid or autoimmune process all keep the stimulus in place. Sleep-disordered breathing alone is estimated at 936 million adults aged 30 to 69 worldwide, 425 million of them moderate to severe Benjafield 2019, and no anti-inflammatory on this page competes with an oxygen desaturation index of 30 an hour.
2. Whether this is inflammation at all, or a different receptor system wearing the same words. The pathway's own framing is the useful one: fog with intact attention behaves differently from a genuine attentional deficit, and the two route to different shelves. A stimulant makes both feel better for four hours, which is exactly why the distinction has to be made before anything is bought rather than after.
3. Membrane composition, which is substrate-limited and turns over on a half-life of months. Docosahexaenoic acid is a structural constituent of neuronal phospholipid rather than a signal, concentrated at the synapse in phosphatidylethanolamine and phosphatidylserine by lysophospholipid acyltransferases. Turnover of a brain phospholipid pool is measured in months, so this lever cannot express itself inside a four-week trial of anything.
4. Systemic inflammatory tone, which the brain reads as a cytokine signal. Circulating IL-6 and TNF cross into the brain by saturable transport and by the circumventricular organs, and vagal afferents signal peripheral cytokines directly. That is the route by which a gut or a joint changes cognition, and it is why the read-out for this page is a peripheral one.
5. The compounds, last, and with a ceiling of 40 people over 18 months. The single best-designed positive result in this whole category is 40 non-demented adults aged 51 to 84 taking a bioavailable curcumin for 18 months, where verbal memory improved with an effect size of 0.63 (P=0.002) against 0.06 (P=0.8) on placebo Small 2018. Forty people. That is the top of the evidence for this shelf rather than the middle of it, and it took 18 months to find.

The order to run these in, and what has to be true first

Take the driver away first, then supply the membrane, then modulate the glia. Running that backwards is how somebody spends nine months on Luteolin with an untreated apnea underneath it.

1. Settle the four cheap questions. HbA1c (Hemoglobin A1c) for the glycemic driver, TSH (Thyroid-Stimulating Hormone) with Free T4 (Thyroxine) for the endocrine one, hs-CRP (High-Sensitivity C-Reactive Protein) for whether there is measurable systemic inflammation to begin with, and Ferritin because iron deficiency produces a fog that no glial compound touches. Snoring with witnessed apneas is a sleep study, not a blood test, and that referral is free.
2. Substrate before signal. Omega-3 (Fish Oil) supplies the EPA and DHA the rest of this page is downstream of, and Phosphatidylserine supplies the head group DHA is esterified into. Both are structural, and phospholipid turnover in brain runs over months rather than over the 4 weeks people judge on.
3. Then resolution, which is a different molecule from the substrate and a different enzyme step. SPMs (Pro-Resolving Mediators) are the enzymatic oxidation products of EPA and DHA made by 15-lipoxygenase and 5-lipoxygenase, and they terminate an inflammatory program rather than suppressing its initiation. Taking more fish oil is not a way of taking a resolvin, because the conversion step is enzyme-limited and not substrate-limited.
4. Then the glial modulators, in order of human data, which runs from one crossover trial (n=31) down to none. Low Dose Naltrexone at the 3 to 4.5 mg range is proposed to act as a TLR4 antagonist on microglia rather than as the opioid antagonist it is at 50 mg, and its one placebo-controlled crossover in 31 women reduced pain by 28.8% against 18.0% (P=0.016) Younger 2013. That is a pain end point, in fibromyalgia, in a very small sample, and extending it to cognition is extrapolation from a shared mechanism, not evidence.
5. Palmitoylethanolamide (PEA) and Luteolin sit on the same mast-cell and glial axis, and both act at nuclear receptors. PEA is a PPAR-alpha agonist and an endogenous fatty acid amide hydrolyzed by NAAA, which is why ultramicronized preparations are argued for. Luteolin is a flavone with the standard flavonoid problem, which is that oral bioavailability is dominated by phase II conjugation in the enterocyte within 30 minutes of absorption.
6. Curcumin belongs here for its 18-month trial, not for its test-tube data. Free curcumin in plasma after 1000 mg of unformulated powder is essentially unmeasurable; a phytosome or a piperine co-administration is not marketing, it is what makes the molecule exist systemically at all. Meta-analysis of turmeric extracts is positive for joint pain at around 1000 mg/day Daily 2016, which is the closest thing to a dose anchor this pathway has.
7. NAC, Sulforaphane (Crucera-SGS), Astaxanthin and Ergothioneine are the redox layer, and three of the four act on one transcription factor. NAC is cysteine substrate for glutathione synthesis, sulforaphane modifies cysteine residues on KEAP1 to release Nrf2, and ergothioneine has its own transporter, OCTN1, expressed on cells under oxidative stress. Three different arguments, one shelf.
8. VIP, Thymosin Alpha 1, Gotu Kola and Brain Impact Support are last for four different reasons, the first two having a plasma clearance measured in minutes, and the first two are genuine immunomodulators whose human data is in conditions that are not this one.

What gets bought for this that cannot move it

Antioxidant capacity measured in a cuvette predicts nothing about a brain. The category fails structurally: a polyphenol has to survive gastric acid, escape UGT and SULT conjugation in the enterocyte and the liver, then cross an endothelium with tight junctions and efflux transporters. Most of the shelf clears the first hurdle and none of the rest, and an ORAC value on a label reports the powder's chemistry and says nothing about bioavailability in a person.

Omega-3 is the option on this page whose reputation most exceeds its per-goal prediction. In 402 randomized adults with mild to moderate Alzheimer disease, 2 g/day of DHA for 18 months produced an ADAS-cog change of 7.98 points against 8.27 on placebo (P=0.41) Quinn 2010. Read that as a ceiling on rescue, not as a verdict on membrane composition: a structural nutrient given after the structure is gone is being asked to do a job it was never the mechanism for.

Suppression is not resolution, and the difference shows up 4 to 8 weeks in. Blocking cyclooxygenase removes prostaglandin production including the 15-lipoxygenase-dependent switch that generates resolvins and protectins. A reader who is on a daily NSAID and adding SPMs (Pro-Resolving Mediators) is running two halves of one pathway against each other, because cyclooxygenase inhibition removes the substrate the resolution branch needs.

And if attention is the actual complaint, this is the wrong page. Fog that lifts with caffeine and returns at 2 pm is a catecholamine and cerebral perfusion question, not a glial one; Catecholamine & dopaminergic drive and Cerebral metabolism & blood flow are the routers for it. Fog with loud snoring, morning headache and a partner who has watched you stop breathing is What's keeping you awake — the upstream causes, and nothing on this shelf substitutes for that.

How you would know it was working, on a real read-out and a real timescale

This page makes one prediction that can be wrong, and it is cheap to test: if glial inflammation is what is degrading cognition here, the peripheral inflammatory marker and the symptom should move in the same eight-week block. If fog lifts at 8 weeks while the marker sits still, whatever helped was not the mechanism on this page.

• hs-CRP (High-Sensitivity C-Reactive Protein) at baseline and 8 weeks, on the same assay. C-reactive protein is an IL-6-driven hepatic acute-phase protein with a plasma half-life near 19 hours, so it tracks the driver almost in real time. A value that has not moved in 8 weeks is evidence the driver has not moved, which is a more useful finding than a symptom diary. Anything above 10 mg/L is an acute event and should not be read as chronic tone.
• HbA1c (Hemoglobin A1c) at 12 weeks, never sooner. Glycated hemoglobin reports the preceding 8 to 12 weeks because the erythrocyte it is measured on lives about 120 days, and roughly half the value is set by the most recent month. A retest at 4 weeks is not an early answer, it is a misread of the assay.
• F2-Isoprostane / Creatinine (Urine) if oxidative load is the specific claim being made. F2-isoprostanes are non-enzymatic peroxidation products of arachidonic acid and are the least manipulable oxidative-stress measure available; they are also the one that will refuse to move on a supplement that raises a paper antioxidant score.
• TSH (Thyroid-Stimulating Hormone) with Free T4 (Thyroxine) once, and Ferritin with the same draw. Both exist here to be normal, and a normal pair closes the question for 12 months. The purpose of a negative result is to stop a reader spending two years on a glial hypothesis while a ferritin of 9 ng/mL explains the whole complaint.
• pTau-217 (AD-Detect) and APOE Genotyping answer a different question and should be treated that way. They speak to whether an amyloid and tau process is present, not to whether this month's fog is inflammatory, and reading them as a supplement read-out is a category error in both directions.

What will fool you. Subjective cognition over a 12-week window is dominated by the previous night's sleep and by the season, not by the intervention. Rate the fog at the same hour on the same day of the week for 8 weeks, and never on a Monday after a short night. A curcumin phytosome and an unformulated turmeric powder at the same labeled milligrams are not the same exposure, so a null result on the cheap version is a null result about the formulation and says nothing about the molecule.

Sources read for these sections

• Quinn JF. Docosahexaenoic acid supplementation and cognitive decline in Alzheimer disease: a randomized trial. JAMA 2010;304(17):1903-11 · PMID 21045096
• Small GW. Memory and Brain Amyloid and Tau Effects of a Bioavailable Form of Curcumin in Non-Demented Adults: A Double-Blind, Placebo-Controlled 18-Month Trial. American Journal of Geriatric Psychiatry 2018;26(3):266-277 · PMID 29246725
• Younger J. Low-dose naltrexone for the treatment of fibromyalgia: findings of a small, randomized, double-blind, placebo-controlled, counterbalanced, crossover trial assessing daily pain levels. Arthritis and Rheumatism 2013;65(2):529-38 · PMID 23359310
• Daily JW, et al. Efficacy of Turmeric Extracts and Curcumin for Alleviating the Symptoms of Joint Arthritis: A Systematic Review and Meta-Analysis of Randomized Clinical Trials. Journal of Medicinal Food, 2016 · PMID 27533649
• Benjafield AV. Estimation of the global prevalence and burden of obstructive sleep apnoea: a literature-based analysis. Lancet Respiratory Medicine 2019;7(8):687-698 · PMID 31300334